"Covaxin" from_date:2012

Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. India started its vaccination programme for Coronavirus-19 infection (COVID-19) on 16 January 2021 with CovishieldTM (Oxford/Astra Zeneca vaccine manufactured by Serum Institute of India) and Covaxin ® (Bharat Biotech, India). We designed the present study )*100. The mean age (SD) of the study participants was 32.3 (8.3) years; majority of these individuals had taken Covishield TM (99.0%) and only 0.9% (n = 27) had taken Covaxin ®. The incidence rate in the overall population was 0.067/100 person-days (PD). The incidence rate was significantly higher in the unvaccinated/partially vaccinated group compared with the fully vaccinated group (0.0989 / 100 PD

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study. Primary SARS-CoV-2 vaccination has been shown to wane with time and provide lower protection from disease with new viral variants, prompting the WHO to recommend the administration of booster doses. We determined the safety and immunogenicity of homologous or heterologous boosters with ChAdOx1 nCoV-19 (COVISHIELD™) or BBV152 (COVAXIN®), the two vaccines used widely for primary immunization in India, in participants who had already received two primary doses of these vaccines. Participants primed with two doses each of COVISHIELD™ or COVAXIN® 12-36 weeks previously, were randomised

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin(®)). One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike intramuscular vaccines, intranasal COVID-19 vaccines may offer this by generating mucosal immunity. In this open-label, randomised, multicentre, phase 3 clinical trial (CTRI/2022/02/40065; ClinicalTrials.gov: NCT05522335), healthy adults were randomised to receive two doses, 28 days apart, of either intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154) or licensed intramuscular vaccine, Covaxin. Between April 16 and June 4, 2022, we enrolled 3160 subjects of whom, 2971 received 2 doses

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. Covaxin/BBV152 is one of the most widely used vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and one of the few vaccines used extensively in low- and middle-income countries (LMIC). We investigated the effect of Covaxin on the SARS-CoV-2 specific IgG and IgA and neutralizing antibody (NAb) levels at baseline (M0) and at Months 1 (M1), 2 (M2), 3 (M3), 4 (M4), 6 (M6) and 12 (M12) following vaccination in healthcare workers. In addition, we also examined the NAb levels against variant lineages of B.1.617.2 (Delta, India), B.1.617.2.1 (Delta Plus, India), B.1.351 (Beta, SA), B.1.1.7 (Alpha, UK) and B.1.1.529 (Omicron). Covaxin induces enhanced SARS-CoV

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study. India introduced BBV152/Covaxin and AZD1222/Covishield vaccines in January 2021. We estimated the effectiveness of these vaccines against severe COVID-19 among individuals aged ≥45 years. We did a multi-centric regression model to calculate the adjusted odds ratios (aOR) with a 95% confidence interval (CI) after adjusting for relevant known confounders. We enrolled 1143 cases and 2541 control patients. The VE of complete vaccination was 85% (95% CI: 79-89%) with AZD1222/Covishield and 71% (95% CI: 57-81%) with BBV152/Covaxin. The VE was highest for 6-8 weeks between two doses of AZD1222/Covishield (94%, 95% CI

Is the Bharat Biotech (Covaxin) vaccine going to make a difference? Selected questions and answers about Covid-19 vaccines. Peter English's random musings: Is the Bharat Biotech (Covaxin) vaccine going to make a difference? Selected questions and answers about Covid-19 vaccines.

Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization options against SAR-CoV-2 Virus infection. This is an open -label single-arm single-center protocol designed to provide expanded access and evaluate the safety of COVID-19 Vaccine, COVAXIN™ (BBV152) in adults, who either decline or do not qualify for current m-RNA based Covid19 vaccines and whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and development of COVID-19.Each participant will receive a 2-dose regimen

COVAXIN in a Pediatric Cohort The study is designed to evaluate the safety, reactogenicity and immunogenicity of three groups ages ≤18 - >12, ≤12 ->6, ≤ 6 - >2 years of healthy volunteers who receive two doses of the whole virion inactivated SARS-CoV-2 virus vaccine (COVAXIN®) 28 days apart.Data will be un-blinded to the third party bio-statistician and an interim analysis will be performed on day 56 for Immunogenicity, Safety and submitted to CDSCO. Study design: A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity, of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers ages ≤18 to ≥2 Years.A total sample size of 525 healthy volunteers.The study is designed to evaluate the safety, reactogenicity

for cases <2 years of age at the time of disease onset. Annex: RESPISURV metadata Page 23 of 95 Brand of last received COVID-19 vaccination dose Field: BrandLastCOVID19Dose Coded value list name: VaccineCOVID Co ding: AZ = AstraZeneca - Vaxzevria BECNBG = Beijing CNBG - BBIBP-CorV BECOV2A = Biological E – Corbeva BHACOV = Bharat - Covaxin BIMER = Hipra - Bimervax CAN = CanSino - Convidecia CHU = Chumakov

= AstraZeneca - Vaxzevria BECNBG = Beijing CNBG - BBIBP-CorV BECOV2A = Biological E – Corbeva BHACOV = Bharat - Covaxin BIMER = Hipra - Bimervax CAN = CanSino - Convidecia CHU = Chumakov - Covi-Vac COM = Pfizer BioNTech - Comirnaty COMBA.1 = Pfizer BioNTech - Comirnaty Original/Omicron BA.1 COMBA.4-5 = Pfizer BioNTech - Comirnaty Original/Omicron BA.4/BA.5 COMBIV = Pfizer BioNTech-Comirnaty Bivalent (Orig

by Pfizer or Moderna 82 to 91% 96% 88% Sinovac followed by AZ 74% (43 to 99) Symptomatic Infection (reported when data on “any infection” is limited) Pfizer 84 to 88% 84 to 88% 63 to 94% Moderna 88% 87% AstraZeneca 10%** 65% 61 to 92% Johnson & Johnson 51%* Novavax 86% 43%** Sinovac 59% Covaxin 50% AZ followed by Pfizer or Moderna 67 to 79% Transmission Pfizer 70 to 82

(16). In total, 487 participants who tested positive for COVID-19 in a single hospital responded, with a mean age of 39 years, 41% female, and 59% of participants had 2 doses of a COVID-19 vaccine (the majority had Covaxin), 17% had one dose, and 25% were unvaccinated. The analysis was adjusted for age, sex, occupation, body mass index, substance use, past COVID-19 infection, comorbidities, number , coagulation, fatigue, gastrointestinal disorders, kidney disorders, mental health disorders, metabolic disorders, musculoskeletal disorders, neurologic disorders, and pulmonary disorders) Arjun (16) India, April to September 2021 Adults with positive COVID-19 test (RT-PCR) from a hospital n=487 (122 unvaccinated, 287 vaccinated [doses NR]) Covaxin (majority) Self-reported long COVID symptoms (including

% (95%CI: 5.3-7.1). Covishield vaccine was received by most participants (81.3%, 2380) followed by Covaxin (12.3%, 361) and Pfizer manufactured vaccine (0.03,1). The coverage for first, second, and booster doses of the vaccine was 98.2% (2902), 94.8% (2802), and 10.7% (315) respectively. The risk of reinfection at 12 months or more among participants with two doses of vaccine was 1.6% (46/2802, 95%CI